Education ▼

SPECIALTY TOPICS

CURRENTLY VIEWING
Mantle Cell Lymphoma

Breast Cancer

Gastrointestinal Cancer

Colorectal Cancer

Ovarian Cancer

Prostate Cancer

Precision Medicine in Oncology^®

Neoadjuvant HER2+

More >>

Mantle Cell Lymphoma

Novel Agents, Combos Transforming Treatment in MCL and CLL

James N. Gerson, MD, discusses exciting updates in mantle cell lymphoma and chronic lyphocytic leukemia and other potentially practice-changing trials on the horizon.
Read More >>

Long-Term Data Highlight Poor Prognosis With TP53-Mutant MCL

BTK Combos Potentially Poised to Be New Standard MCL Treatment

Targeted Agents Continue to Advance in MCL, With CAR T on the Horizon

Andre Goy: Giving Patients Strength to Fight

Intriguing Strategies Taking Shape in Mantle Cell Lymphoma

View More Stories >>

View Conference Coverage

2019 Lynn Sage Breast Cancer Symposium

2019 ESMO Congress

17th International Myeloma Workshop

2019 Society of Hematologic Oncology Annual Meeting

2019 World Conference on Lung Cancer

Dr. Gerson on Strategies Aimed at Alleviating Toxicity in Older Patients With MCL

Dr. Wang on Toxicity Profiles of Ibrutinib, Acalabrutinib, and Zanubrutinib in MCL

Dr. Gerson on the Watch-and-Wait Approach in MCL

Dr. Rule on the Future Therapeutic Landscape of MCL

OncLive houses thousands of videos that provide updates and information.
See more Videos

Practical Advice on the Future Management of MCL

R/R MCL: Synchronizing Older and Newer Therapeutic Strategies

$Selection of a BTK Inhibitor in Relapsed/Refractory MCL$

Selection of a BTK Inhibitor in Relapsed/Refractory MCL

Mantle Cell Lymphoma: An Overview on Frontline Therapy

Highlights from ASH 2017: Mantle Cell Lymphoma

Investigational Treatment in Mantle Cell Lymphoma

Future Therapy: Bruton's TKI Containing Combinations in MCL

OncLive houses thousands of videos that provide updates and information.
See more Videos

New and Emerging BTK Inhibitors in Mantle Cell Lymphoma

First-Generation BTK Inhibition in Mantle Cell Lymphoma

Advice for Future Management of Mantle Cell Lymphoma

Non-BTKi Agents' Role in Mantle Cell Lymphoma

MCL: Novel BTK Inhibitor Combination Strategies

$Identifying Unmet Needs in Relapsed/Refractory MCL$

Differentiating BTK Inhibitor Mechanisms of Action in MCL

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Programs

Ibrutinib in Relapsed Mantle Cell Lymphoma

Drs Danilov, Goy, Leonard, Pagel, and Schuster, discuss ibrutinib (Imbruvica) as a treatment in relapsed mantle cell lymphoma. View Now

Treatments for Relapsed Mantle Cell Lymphoma

Brad S. Kahl, MD, and Richard R. Furman, MD, explain available treatment options for relapsed mantle cell lymphoma. View Now

Featured Video

Dr. Esteva on the Future of Biosimilars in Breast Cancer

Francisco J. Esteva, MD, PhD, director, breast medical oncology program, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, discusses the future use of biosimilars in breast cancer within the United States. View now

FDA Approval in Myeloma, Label Update in HER2+ Breast Cancer, Breakthrough Status in Prostate Cancer, and More